相关实验视频

Updated: Jun 28, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

非小细胞肺癌中的EGFR降解剂:突破和未解决的问题

Jiayi Shen¹, Liping Chen¹, Jihu Liu¹

¹Key Laboratory of Organo-Pharmaceutical Chemistry of Jiangxi Province, Gannan Normal University, Ganzhou, Jiangxi, China.

Chemical biology & drug design

|April 12, 2024

概括

新的EGFR降解剂,如PROTACs,在克服非小细胞肺癌 (NSCLC) 中的C797S突变方面显示出希望. 与传统的表皮生长因子受体 (EGFR) 抑制剂相比,这些向疗法提供了更好的疗效和毒性概况.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

表皮生长因子受体 (EGFR) 是非小细胞肺癌 (NSCLC) 的验证标.
作为第三代EGFR抑制剂的奥西默提尼布因EGFRC797S突变而面临耐药性,这是一个未满足的临床需求.
第四代EGFR抑制剂正在开发中,但缺乏临床疗效数据.

研究的目的:

审查EGFR的结构性质,耐药性机制和突变.
专注于 EGFR 向性降解剂的最新进展,包括 PROTAC.
讨论EGFR降解剂在NSCLC中的优势和挑战.

主要方法:

关于EGFR抑制剂和耐药机制的文献综述.
对新型EGFR向降解剂的分析,如向蛋白解化学分子 (PROTACs).
降解剂与抑制剂的细胞效能,抑制和毒性概况的比较.

主要成果:

EGFR突变,特别是C797S,对现有疗法如 osimertinib 产生抗性.
来自EGFR-TKI和天然产品的EGFR向降解剂显示出增强的细胞效能和改善的毒性概况.
PROTACs是克服EGFR介导药物耐药性的有希望的策略.

结论:

向EGFR的降解剂为克服NSCLC中C797S介导的耐药性提供了一个潜在的解决方案.
对于EGFR降解剂,需要进一步的研究和临床验证.
向蛋白质降解是药物耐药癌症的新兴治疗方式.

关键词:

发生EGFR突变的原因由于EGFR的耐药性,因此可以抗生.皮肤上生长因子受体 (EGFR)非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.蛋白质分解向的化学分子 (PROTACs)

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...